A CSF-1R blocking antibody monotherapy achieved modest tumour growth inhibition by reducing TAMs and improving the ratio of CD8+ T cells to Tregs in colon adenocarcinoma and melanoma syngeneic tumour models [77]. The gene discussed is CSF1R; the disease is neoplasm.